Salivary Metabolomics of Well and Poorly Controlled Type 1 and Type 2 Diabetes

Table 3

Summary of salivary metabolites differentially expressed in poorly controlled vs. well-controlled type II diabetes.

Metabolite compound ID	VIP	value	Fold change
1490 peaks	0.2–2.4	0.002–0.999	−107, −382
(2S)-3-Hydroxy-1,1-dimethyl-2-pyrrolidiniumcarboxylate	1.6	0.075	−1.5
(3α,4β,8α,12R)-15-Acetoxy-3,4-dihydroxy-12,13-epoxytrichothec-9-en-8-yl 3-methylbutanoate	1.2	0.792	1.1
(3beta)-Gonan-3-yl beta-D-glucopyranoside	1.5	0.302	−1.1
(4Z)-4-(3,3-Dimethyltriazanylidene)-4H-imidazole-5-carboxamide	1	0.344	96.7
(6E)-3,7,11-Trimethyl-6,10-dodecadien-1-yl dihydrogen phosphate	1.4	0.211	−1.2
2,3-Dinor-6-keto-prostaglandin F1 a	1.4	0.364	−1.2
2-Isopropyl-4a-methyl-8-methylenedecahydro-1-naphthalenol	1.5	0.117	10
2-Oxo-4-methylthiobutanoic acid	1.9	0.093	−1.4
3-Hydroxycoumarin	1.3	0.427	−1.1
3-Hydroxybenzoic acid	1.6	0.267	−1.3
3-Hydroxyhexadecanoylcarnitine	1.4	0.362	−1.2
8-Isoprostane	1.6	0.159	−1.2
Androsterone glucuronide	1.3	0.616	−1.1
Arginyl-aspartate	2.1	0.023	−1.4
Coumarin	2	0.038	−3.1
DL-Serine	1.7	0.07	−1.4
Deoxypyridinoline	1.6	0.054	1.4
Endomorphin-2	1.2	0.734	1.1
GPA (4:0/18:3)	1.2	0.638	−1.1
Hippuric acid	1.6	0.108	−1.3
L-Valine	2.1	0.037	−1.3
Lauramide	1.4	0.339	−1.1
LysoPE (0:0/16:0)	1.1	0.902	−1
Lysyl-asparagine	1.3	0.351	−1.2
MG (11:0/0:0/0:0)	1.5	0.154	−1.4
MGDG (20:5/14:1)	1.6	0.236	−1.2
MGDG (4:0/5:0)	2.3	0.013	−1.5
Methylimidazoleacetic acid	1.9	0.034	1.7
N-Glycolylneuraminic acid	1.2	0.264	2.3
N-Methylserotonin	2.1	0.016	−1.5
N6,N6,N6-Trimethyl-L-lysine	1.6	0.118	−1.6
Neurine	1.2	0.923	1
Pyrimidine	1.8	0.043	1.8
Pyrrolidine	1.2	0.587	−1.2
Saccharopine	1.9	0.065	−1.3
Salicylic acid	1.4	0.17	−1.3
Stearic acid	1.6	0.071	2.4
Ureidosuccinic acid	1.5	0.168	−1.3
Lauryl sulfate	1.6	0.105	−1.4

t-test with Satterthwaite correction. A positive fold change indicates mean of poorly controlled > mean of well-controlled.